<html>
  <head>
    <title></title>
  <meta name="GENERATOR" content="MSHTML 11.00.9600.18838">
    <!-- Licensed to: emergent#1
         Document created using EDGARfilings PROfile 5.0.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body text="#000000" bgcolor="#ffffff" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">
  <div>
    <div style="LINE-HEIGHT: 13.7pt"><br style="LINE-HEIGHT: 13.7pt">
    </div>
    <div style="FONT-SIZE: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 20.5pt">UNITED STATES</div>
    <div style="FONT-SIZE: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 20.5pt">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">WASHINGTON, D.C. 20549</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 20.5pt">FORM&#160;8-K</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt">CURRENT REPORT</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Date of Report (Date of earliest event reported):<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif;
        FONT-WEIGHT: bold">&#160;January 23, 2019</font></div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 18pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 20.5pt">EMERGENT BIOSOLUTIONS INC.</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">(Exact name of registrant as specified in its charter)</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z56a411050f5f4f2d9f3cbbb4e5519b6f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%; BORDER-COLLAPSE: collapse">

        <tr>
          <td style="WIDTH: 32.01%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">DELAWARE</div>
          </td>
          <td style="WIDTH: 2%; VERTICAL-ALIGN: bottom">&#160;</td>
          <td style="WIDTH: 32%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">001-33137</div>
          </td>
          <td style="WIDTH: 2%; VERTICAL-ALIGN: bottom">&#160;</td>
          <td style="WIDTH: 32%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">14-1902018</div>
          </td>
        </tr>
        <tr>
          <td style="WIDTH: 32.01%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">(State or other jurisdiction</div>
          </td>
          <td style="WIDTH: 2%; VERTICAL-ALIGN: bottom">&#160;</td>
          <td style="WIDTH: 32%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">(Commission File Number)</div>
          </td>
          <td style="WIDTH: 2%; VERTICAL-ALIGN: bottom">&#160;</td>
          <td style="WIDTH: 32%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">(IRS Employer</div>
          </td>
        </tr>
        <tr>
          <td style="WIDTH: 32.01%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">of incorporation)</div>
          </td>
          <td style="WIDTH: 2%; VERTICAL-ALIGN: bottom">&#160;</td>
          <td style="WIDTH: 32%; VERTICAL-ALIGN: top">&#160;</td>
          <td style="WIDTH: 2%; VERTICAL-ALIGN: bottom">&#160;</td>
          <td style="WIDTH: 32%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">Identification No.)</div>
          </td>
        </tr>

    </table>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 0.25pt; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-TOP: 12pt; LINE-HEIGHT: 13.7pt">400 Professional Drive, Suite 400,</div>
    <div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt">Gaithersburg, Maryland 20879</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>(Address of principal executive
      offices, including zip code)</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">(240) 631-3200</font></div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">(Registrant's telephone number, including area code)</div>
    <div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
    </div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">N/A</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">(Former name or former address, if changed since last report)</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
      any of the following provisions (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">see</font> General Instruction A.2. below):</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font>&#160;&#160;&#160; Written communications pursuant to Rule&#160;425 under
      the Securities Act (17 CFR 230.425)</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font>&#160;&#160;&#160; Soliciting material pursuant to Rule&#160;14a-12 under
      the Exchange Act (17 CFR 240.14a-12)</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font>&#160;&#160;&#160; Pre-commencement communications pursuant to
      Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#160;</div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font>&#160;&#160;&#160; Pre-commencement communications pursuant to
      Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</div>
    <div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 13.1pt"><br style="LINE-HEIGHT: 13.1pt">
      <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
      </font>Indicate by check mark whether the registrant is an emerging growth company as defined in&#160;Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>
    <div style="MARGIN-BOTTOM: 12pt; FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 13.1pt">Emerging growth company &#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font></div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
      complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9744;</font></div>
    <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
      <div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
        <hr noshade="noshade" style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
    </div>
    <div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="font-weight: bold;">Item 5.02.&#160; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font>
      <div style="text-align: left; line-height: 11.4pt; margin-top: 12pt; margin-bottom: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Appointment of Robert G. Kramer, Sr. to the Board of Directors</font></div>
      <div style="text-align: justify; line-height: 11.4pt; margin-top: 12pt; margin-bottom: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On January 23, 2019, the Board of Directors (the &#8220;Board&#8221;) of Emergent
          BioSolutions Inc. (the &#8220;Company&#8221;) appointed Robert G. Kramer, Sr., as a Class III director of the Company effective April 1, 2019, with an initial term expiring at the 2021 annual meeting of stockholders, to fill the anticipated vacancy created
          by the previously announced retirement of Daniel J. Abdun-Nabi. The Board also appointed Mr. Kramer as a member of its Strategic Operations Committee, effective upon his appointment to the Board.&#160; Mr. Kramer was not selected pursuant to any
          arrangement or understanding with any other person. There are no transactions in which the Company is a party and in which Mr. Kramer has a material interest subject to disclosure under Item 404(a) of Regulation S-K.&#160; Mr. Kramer previously
          entered into the Company&#8217;s standard form of Indemnification Agreement, a form of which was filed as Exhibit 10 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on January 18, 2013.</font></div>
      <div style="text-align: justify; line-height: 11.4pt; margin-top: 12pt; margin-bottom: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Mr. Kramer currently serves as the Company&#8217;s President and Chief Operating
          Officer. On January 2, 2019, the Company promoted Mr. Kramer to the role of President and Chief Executive Officer, effective as of April 1, 2019, to succeed Mr. Abdun-Nabi. Mr. Kramer will not participate in the Company&#8217;s compensation programs
          for non-employee directors. For a description of the compensation that Mr. Kramer will receive as President and Chief Executive Officer, refer to the Company&#8217;s Current Report on Form 8-K, filed with the Securities and Exchange Commission on
          January 4, 2019.</font></div>
      <div style="text-align: left; line-height: 11.4pt; margin-top: 12pt; margin-bottom: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 7.01.&#160; Regulation FD Disclosure.</font></div>
      <div style="text-align: justify; line-height: 11.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On January 24, 2019, the Company issued a press release regarding the appointment to the Board of Mr. Kramer, a copy
          of which is attached as Exhibit 99 to this Form 8-K.</font></div>
      <div style="line-height: 11.4pt;"><br style="line-height: 11.4pt;">
      </div>
      <div style="line-height: 11.4pt;"><br style="line-height: 11.4pt;">
      </div>
      <div style="text-align: left; line-height: 11.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 9.01. Financial Statements and Exhibits.</font></div>
      <div style="text-align: left; line-height: 11.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font></div>
      <div style="text-align: left; line-height: 11.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)<font style="font-family: 'Times New Roman', serif; font-size: 3pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>Exhibits.</font></div>
      <div style="text-align: left; line-height: 11.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font></div>
      <div style="text-align: left; line-height: 11.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font></div>
      <table cellspacing="0" cellpadding="0" id="zb1cdc6f86f37467891e50ad8932746bb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse;">

          <tr>
            <td style="width: 6.12%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: left; line-height: 9.1pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Exhibit<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
                  </font>No.</font></div>
            </td>
            <td style="width: 2.04%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 3.4pt;"><font style="font-family: 'Times New Roman', serif; font-size: 3pt; font-weight: bold;">&#160;</font></div>
            </td>
            <td style="width: 90.82%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: center; line-height: 9.1pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Description</font></div>
            </td>
            <td style="width: 1.01%; vertical-align: bottom;">
              <div style="text-align: center; line-height: 3.4pt;"><font style="font-family: 'Times New Roman', serif; font-size: 3pt; font-weight: bold;">&#160;</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 6.12%; vertical-align: top;">
              <div style="text-align: left; text-indent: -10.1pt; margin-left: 10.1pt; line-height: 11.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font></div>
            </td>
            <td style="width: 2.04%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 11.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font></div>
            </td>
            <td style="width: 90.82%; vertical-align: bottom;">
              <div style="text-align: right; line-height: 11.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font></div>
            </td>
            <td style="width: 1.01%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 11.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font></div>
            </td>
          </tr>
          <tr>
            <td style="width: 6.12%; vertical-align: top;">
              <div style="text-align: left; text-indent: -10.1pt; margin-left: 10.1pt; line-height: 11.4pt;"><a href="exhibit_99.htm"><font style="font-size:
                    10pt; font-family: 'Times New Roman', Times, serif;">99</font></a></div>
            </td>
            <td style="width: 2.04%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 3.4pt;"><font style="font-family: 'Times New Roman', serif; font-size: 3pt;">&#160;</font></div>
            </td>
            <td style="width: 90.82%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 11.4pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Press release, dated January 24, 2019, announcing appointment of Robert G. Kramer, Sr. as a director.</font></div>
              <div style="line-height: 13.7pt;"><font style="line-height: 13.7pt;">&#160;</font></div>
            </td>
            <td style="width: 1.01%; vertical-align: bottom;">
              <div style="text-align: left; line-height: 3.4pt;"><font style="font-family: 'Times New Roman', serif; font-size: 3pt;">&#160;</font></div>
            </td>
          </tr>

      </table>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
    </div>
    <div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
    </div>
    &#160;
    <div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
    </div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 11.4pt">SIGNATURE</div>
    <div style="LINE-HEIGHT: 13.7pt"><br style="LINE-HEIGHT: 13.7pt">
    </div>
    <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 11.4pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
      behalf by the undersigned hereunto duly authorized.</div>
    <div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
    </div>
    <div style="LINE-HEIGHT: 13.7pt"><br style="LINE-HEIGHT: 13.7pt">
    </div>
    <table cellspacing="0" cellpadding="0" id="za8a7125039ea430294f412aacf80c74d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%; BORDER-COLLAPSE: collapse">

        <tr>
          <td style="WIDTH: 51.35%; VERTICAL-ALIGN: top">&#160;</td>
          <td style="WIDTH: 48.65%; VERTICAL-ALIGN: top" colspan="2">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">EMERGENT BIOSOLUTIONS INC.</div>
          </td>
        </tr>
        <tr>
          <td style="WIDTH: 51.35%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#160;</div>
          </td>
          <td style="WIDTH: 4.64%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#160;</div>
          </td>
          <td style="WIDTH: 44.02%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="WIDTH: 51.35%; VERTICAL-ALIGN: top">
            <div style="LINE-HEIGHT: 13.7pt">Dated: January 24, 2019</div>
          </td>
          <td style="WIDTH: 4.64%; VERTICAL-ALIGN: top">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">By:</div>
          </td>
          <td style="WIDTH: 44.02%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
            <div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt">/s/ RICHARD S. LINDAHL</div>
          </td>
        </tr>
        <tr>
          <td style="WIDTH: 51.35%; VERTICAL-ALIGN: top">&#160;</td>
          <td style="WIDTH: 4.64%; VERTICAL-ALIGN: top">&#160;</td>
          <td style="WIDTH: 44.02%; VERTICAL-ALIGN: top">
            <div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Name:&#160;&#160;&#160;&#160;&#160;&#160; </font>Richard S. Lindahl</div>
            <div style="TEXT-ALIGN: left; LINE-HEIGHT: 11.4pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Title:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Executive Vice
                President, Chief Financial Officer and Treasurer<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
                </font></font><font style="LINE-HEIGHT: 11.4pt">&#160;</font></div>
          </td>
        </tr>
        <tr>
          <td style="WIDTH: 51.35%; VERTICAL-ALIGN: top">&#160;</td>
          <td style="WIDTH: 4.64%; VERTICAL-ALIGN: top">&#160;</td>
          <td style="WIDTH: 44.02%; VERTICAL-ALIGN: top">&#160;</td>
        </tr>

    </table>
    <div style="LINE-HEIGHT: 11.4pt"><br style="LINE-HEIGHT: 11.4pt">
    </div>
    <div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">&#160;</div>
  </div>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "form8-k-0124019.htm", "secsgml_size_bytes": 24637}]
{"company-data": {"conformed-name": "Emergent BioSolutions Inc.", "cik": "0001367644", "assigned-sic": "2834", "irs-number": "141902018", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33137", "film-number": "19538607"}, "business-address": {"street1": "400 PROFESSIONAL DR, SUITE 400", "city": "GAITHERSBURG", "state": "MD", "zip": "20879", "phone": "240-631-3200"}, "mail-address": {"street1": "400 PROFESSIONAL DR, SUITE 400", "city": "GAITHERSBURG", "state": "MD", "zip": "20879"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 23, 2019
EMERGENT BIOSOLUTIONS INC.
(Exact name of registrant as specified in its charter)
DELAWARE
001-33137
14-1902018
(State or other jurisdiction
(Commission File Number)
(IRS Employer
of incorporation)
Identification No.)
400 Professional Drive, Suite 400,
Gaithersburg, Maryland 20879
(Address of principal executive
      offices, including zip code)
(240) 631-3200
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
      any of the following provisions (
see
General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under
      the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under
      the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to
      Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to
      Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
      complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Robert G. Kramer, Sr. to the Board of Directors
On January 23, 2019, the Board of Directors (the "Board") of Emergent
          BioSolutions Inc. (the "Company") appointed Robert G. Kramer, Sr., as a Class III director of the Company effective April 1, 2019, with an initial term expiring at the 2021 annual meeting of stockholders, to fill the anticipated vacancy created
          by the previously announced retirement of Daniel J. Abdun-Nabi. The Board also appointed Mr. Kramer as a member of its Strategic Operations Committee, effective upon his appointment to the Board.  Mr. Kramer was not selected pursuant to any
          arrangement or understanding with any other person. There are no transactions in which the Company is a party and in which Mr. Kramer has a material interest subject to disclosure under Item 404(a) of Regulation S-K.  Mr. Kramer previously
          entered into the Company's standard form of Indemnification Agreement, a form of which was filed as Exhibit 10 to the Company's Current Report on Form 8-K, filed with the SEC on January 18, 2013.
Mr. Kramer currently serves as the Company's President and Chief Operating
          Officer. On January 2, 2019, the Company promoted Mr. Kramer to the role of President and Chief Executive Officer, effective as of April 1, 2019, to succeed Mr. Abdun-Nabi. Mr. Kramer will not participate in the Company's compensation programs
          for non-employee directors. For a description of the compensation that Mr. Kramer will receive as President and Chief Executive Officer, refer to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on
          January 4, 2019.
Item 7.01.  Regulation FD Disclosure.
On January 24, 2019, the Company issued a press release regarding the appointment to the Board of Mr. Kramer, a copy
          of which is attached as Exhibit 99 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
Description
99
Press release, dated January 24, 2019, announcing appointment of Robert G. Kramer, Sr. as a director.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
      behalf by the undersigned hereunto duly authorized.
EMERGENT BIOSOLUTIONS INC.
Dated: January 24, 2019
By:
/s/ RICHARD S. LINDAHL
Name:
Richard S. Lindahl
Title:
Executive Vice
                President, Chief Financial Officer and Treasurer